On May 16, 2018 Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, reported that data on two of its pipeline programs will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2018, to be held June 1-5 in Chicago, Illinois (Press release, Molecular Templates, MAY 16, 2018, View Source [SID1234526710]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date: Monday, June 4
Time: 8:00am – 11:30am Central Time
Location: Hall A, Poster Board #217
Abstract #:
7580
Session:
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Poster Title: Safety and Efficacy of Anti-CD20 Immunotoxin MT-3724 in Relapsed/Refractory B-cell non-Hodgkin Lymphoma (NHL) in a Phase 1 Study
First Author: Paul A. Hamlin, MD, Memorial Sloan Kettering Cancer Center
The poster summarizes interim results from a Phase I study of B-cell non-Hodgkin’s lymphoma (NHL) patients treated with MT-3724 who had previously relapsed after prior response to anti-CD20 Mab and chemotherapy. The results showed that MT-3724 has clinical anti-tumor activity in heavily pre-treated patients with relapsed or refractory B-cell NHL. Consistent with the mechanism of action, the best activity is observed in patients with rapidly growing diffuse large B-cell lymphoma (DLBCL).
Date: Monday, June 4
Time: 8:00am – 11:30am Central Time
Location: Hall A, Poster Board #394
Abstract #: 2568
Session: Developmental Therapeutics – Clinical Pharmacology & Experimental Therapeutics
Poster Title: Unexpected Pharmacokinetics of Evofosfamide Observed in Phase III MAESTRO Study
First Author: Jack P. Higgins, Ph.D., Molecular Templates, Inc.
This study compares the pharmacokinetic (PK) profile of Evofosfamide from the Phase II and Phase III trials completed in patients with pancreatic ductal adenocarcinoma (PDAC). A new ethanol-based formulation of Evofosfamide was introduced following Phase 2, with the goal of improving drug product solubility. The resultant decrease in drug exposure may explain why the efficacy seen in the Phase 2 study was not replicated in Phase 3.